City of Hope and Translational Genomics Research Institute (TGen) have announced an alliance to make precision medicine a reality for patients. This alliance enables both institutes to complement each other in their common areas of research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen.
Our aim is not only to navigate this changing field, but to lead it.— Jeffrey M. Trent, PhD
Tweet this quote
City of Hope is a pioneer in the fields of bone marrow transplantation, hematologic malignancies, select solid tumors, and diabetes. TGen is a leader in applying genomic analysis and bioinformatics to cancer drug development. Together, City of Hope and TGen will accelerate the speed with which scientists and medical staff convert research discoveries into cures for patients.
“Patients want choices and access to the newest and most advanced care available,” said Robert W. Stone, President and Chief Executive Officer of City of Hope. “City of Hope and TGen share a common vision for improving patient outcomes, and our collaboration will speed cancer cures by rapidly advancing discoveries to define high-risk populations, identifying targets for prevention and treatment, and promoting initiatives that close health-equity gaps.”
“This alliance will enable us to fully deploy genomic-enabled medicine within a modern health-care system to create a disruptive change in the practice of medicine. Our aim is not only to navigate this changing field, but lead it,” said Jeffrey M. Trent, PhD, President and Research Director for TGen.
Together, City of Hope and TGen will cover the bench-to-bedside continuum. Our complementary strengths will propel us to the forefront of personalized medicine….— Steven T. Rosen, MD
Tweet this quote
“Precision medicine is the future of cancer care,” said Steven T. Rosen, MD, Provost and Chief Scientific Officer for City of Hope. “Together, City of Hope and TGen will cover the bench-to-bedside continuum. Our complementary strengths will propel us to the forefront of personalized medicine in alignment with our nation’s ‘Moonshot’ initiative.”
In forming this alliance, City of Hope and TGen will focus on leveraging their respective strengths in patient care and genomics to develop a comprehensive Personalized Hope program to detect disease sooner and improve patient quality of life and survival. Near term, they will focus on leveraging their respective strengths in immunotherapy and genomics to rapidly gain new insights into immune function and expand opportunities for the rational design of new immune interventions.
TGen remains an Arizona-based nonprofit with headquarters in Phoenix. As part of the agreement, TGen will join the City of Hope system by becoming a subsidiary of the City of Hope parent organization. William Post, TGen Board Chairman, will join City of Hope’s Board of Directors, and Dr. Trent will remain President and Research Director at TGen and will report to City of Hope’s CEO Dr. Stone, who has accepted a seat on the TGen Board and will serve as Vice Chairman. ■
